Abstract: The present invention provides a formulation of Coenzyme Q10 that can be re-dispersed from a stable dry powder to formulation to yield a nanodispersion that can be readily aerosolized for inhalation.

Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

Abstract: Provided herein are energy storage devices comprising a first electrode comprising a layered double hydroxide, a conductive scaffold, and a first current collector; a second electrode comprising a hydroxide and a second current collector; a separator; and an electrolyte. In some embodiments, the specific combination of device chemistry, active materials, and electrolytes described herein form storage devices that operate at high voltage and exhibit the capacity of a battery and the power performance of supercapacitors in one device.

Abstract: The invention disclosed herein relates to methods and materials for producing simvastatin and related compounds such as huvastatin. In particular, the disclosure teaches that variants of the LovD acyltransferase polypeptide can be engineered to exhibit properties that facilitate their use in the production of simvastatin and/or huvastatin. The materials and processes disclosed herein are designed so that fermentation facilitates lovastatin being converted to simvastatin and related compounds with minimal modifications.

Abstract: The present disclosure provides compositions including a beta-lactamase inhibitor, pharmaceutical compositions including a beta-lactamase inhibitor, methods of treatment of a condition (e.g., infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.

Abstract: A system for detecting gas leaks and determining their location and size. A data gathering portion of the system utilizes a chosen geometrical configuration to collect path-integrated spectroscopic data over multiple paths around an area. A processing portion of the system applies a transport model together with meteorological data of the area to generate an influence function of possible leak locations on gas detector measurement paths, and applies an inversion model to the influence function, prior data, and the spectroscopic data to generate gas source size and location.

Abstract: In one embodiment, an anterior cervical transarticular fixation implant including a cervical plate including a central body, lateral wings that extend laterally outward from the central body, each lateral wing including a fastener opening configured to receive a fastener configured to thread into vertebrae, and locking mechanisms configured to selectively lock the fasteners in place.

Abstract: A bulk permanent magnetic material may include between about 5 volume percent and about 40 volume percent Fe16N2 phase domains, a plurality of nonmagnetic atoms or molecules forming domain wall pinning sites, and a balance soft magnetic material, wherein at least some of the soft magnetic material is magnetically coupled to the Fe16N2 phase domains via exchange spring coupling. In some examples, a bulk permanent magnetic material may be formed by implanting N+ ions in an iron workpiece using ion implantation to form an iron nitride workpiece, pre-annealing the iron nitride workpiece to attach the iron nitride workpiece to a substrate, and post-annealing the iron nitride workpiece to form Fe16N2 phase domains within the iron nitride workpiece.

Abstract: An electrochemical capacitor includes a pair of electrodes and an electrolyte disposed between the pair of electrodes. At least a first electrode of the pair of electrodes includes a graphene framework film, and the graphene framework film includes interconnected graphene sheets with nanopores formed in the graphene sheets.

Abstract: There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.

Abstract: In alternative embodiments, the invention provides compositions and methods for manipulating the exchange of water and/or carbon dioxide (CO2) through plant stomata by controlling the expression of a novel apoplastic subtilisin-like serine endopeptidase-like protein. In alternative embodiments, the invention provides plants having increased water use efficiency, and drought-resistant plants; and methods for engineering of water transpiration and water use efficiency in plants, and engineering plants with increased water use efficiency and drought-resistant plants.

Abstract: Methods for inducing non-clonal immortalization of normal epithelial cells by directly targeting the two main senescence barriers encountered by cultured epithelial cells. In finite lifespan pre-stasis human mammary epithelial cells (HMEC), the stress-associated stasis barrier was bypassed, and in post-stasis HMEC, the replicative senescence barrier, a consequence of critically shortened telomeres, was bypassed. Early passage non-clonal immortalized lines exhibited normal karyotypes. Methods of efficient HMEC immortalization, in the absence of “passenger” genomic errors, should facilitate examination of telomerase regulation and immortalization during human carcinoma progression, methods for screening for toxic and environmental effect on progression, and the development of therapeutics targeting the process of immortalization.

Abstract: A method of forming a graphene-based material includes: (1) treating a mixture including an etchant and graphene oxide sheets to yield formation of holey graphene oxide sheets; (2) dispersing the holey graphene oxide sheets in a re-dispersal solvent to yield a holey graphene oxide dispersion including the holey graphene oxide sheets; and (3) treating the holey graphene oxide dispersion under reducing conditions to yield self-assembly of the holey graphene oxide sheets into a graphene-based material.

Abstract: The present invention provides a synthetic chemical method for preparing ?-hydroxylated polyunsaturated fatty acids (PUFAs) including 20-hydroxyeicosatetraenoic acid (20-HETE), 20-hydroxyeicosapentaenoic acid (20-HEPE), and 22-hydroxydocosahexaenoic acid (22-HDoHE) and a method of use thereof for treating cancer and macular degeneration.

Abstract: Systems and methods for a hybrid current-mode to voltage-mode integrated circuit. An example integrated circuit embodiment configured according to this disclosure can include: a clock circuit and a logic circuit operatively synchronized with said clock circuit, where the logic circuit has a plurality of sub-circuits. The clock circuit can include a current-mode network tree and a plurality of current-mode-to-voltage-mode converters, each current-mode-to-voltage-mode converter in the plurality of current-mode-to-voltage-mode converters being electrically connected to the current-mode network tree, and each current-mode-to-voltage-mode converter in the plurality of current-mode-to-voltage-mode converters being associated with a respective one of the plurality of sub-circuits.

Abstract: The present invention is a composition and method for making and using a rechargeable multifunctional additive that reduce the formation of biofilms on a surface, the additive can also remain photo and thermally stable by synthesizing one or more N-halamine compounds and adding one or more N-halamine biocidal compounds to a target material prior, during or after the target material is made. The resultant material can be used directly to provide antimicrobial functions and control biofilm formation, or the material can be further processed into an article.

Abstract: A microfluidic device for forming droplets includes at least one ferrofluid reservoir disposed in the microfluidic device and containing a ferrofluid therein. The microfluidic device includes a continuous-phase reservoir disposed in the microfluidic device and containing an oil phase therein and one or more microfluidic channels connecting between the at least one ferrofluid reservoir and the continuous-phase reservoir, the continuous-phase reservoir comprising a step region having an increased height as compared to a height of the one or more microfluidic channels. To form droplets an externally applied magnetic field is applied to the device to pull the ferrofluid into the continuous-phase reservoir, whereby droplets are formed at step region.

Abstract: The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.

Abstract: In one aspect, radioactive nanoparticles are described herein. In some embodiments, a radioactive nanoparticle described herein comprises a metal nanoparticle core, an outer metal shell disposed over the metal nanoparticle core, and a metallic radioisotope disposed within the metal nanoparticle core or within the outer metal shell. In some cases, the radioactive nanoparticle has a size of about 30-500 nm in three dimensions. In addition, in some embodiments, the radioactive nanoparticle further comprises an inner metal shell disposed between the metal nanoparticle core and the outer metal shell. The metal nanoparticle core, outer metal shell, and inner metal shell of the radioactive nanoparticle can have various metallic compositions.

Abstract: Duchenne muscular dystrophy (DMD), which affects 1 in 5,000 male births, is one of the most common genetic disorders of children. This disease is caused by an absence or deficiency of dystrophin protein in striated muscle. The major DMD deletion “hot spots” are found between exon 6 to 8, and exons 45 to 53. Here, a “humanized” mouse model is provided that can be used to test a variety of DMD exon skipping strategies. Among these are, CRISPR/Cas9 oligonucleotides, small molecules or other therapeutic modalities that promote exon skipping or micro dystrophin mini genes or cell based therapies. Methods for restoring the reading frame of exon 44 deletion via CRISPR-mediated exon skipping in the humanized mouse model, in patient-derived iPS cells and ultimately, in patients using various delivery systems are also contemplated. The impact of CRISPR technology on DMD is that gene editing can permanently correct mutations.